Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies

PURPOSE: Testing safety of Delta24-RGD (DNX-2401), an oncolytic adenovirus, locally delivered by convection enhanced delivery (CED) in tumor and surrounding brain of patients with recurrent glioblastoma. PATIENTS AND METHODS: Dose-escalation phase I study with 3+3 cohorts, dosing 10(7) to 1 × 10(11)...

Descripción completa

Detalles Bibliográficos
Autores principales: van Putten, Erik H.P., Kleijn, Anne, van Beusechem, Victor W., Noske, David, Lamers, Cor H.J., de Goede, Anna L., Idema, Sander, Hoefnagel, Daphna, Kloezeman, Jenneke J., Fueyo, Juan, Lang, Frederick F., Teunissen, Charlotte E., Vernhout, René M., Bakker, Cathy, Gerritsen, Winald, Curiel, David T., Vulto, Arnold, Lamfers, Martine L.M., Dirven, Clemens M.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365362/
https://www.ncbi.nlm.nih.gov/pubmed/35176144
http://dx.doi.org/10.1158/1078-0432.CCR-21-3324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365362/
https://www.ncbi.nlm.nih.gov/pubmed/35176144
http://dx.doi.org/10.1158/1078-0432.CCR-21-3324

Ejemplares similares